

Hazel Squires

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3724965/publications.pdf>

Version: 2024-02-01

40
papers

926
citations

430874

18
h-index

454955

30
g-index

41
all docs

41
docs citations

41
times ranked

1621
citing authors

#	ARTICLE	IF	CITATIONS
1	Economic models of community-based falls prevention: a systematic review with subsequent commissioning and methodological recommendations. BMC Health Services Research, 2022, 22, 316.	2.2	5
2	Economic evaluation of community-based falls prevention interventions for older populations: a systematic methodological overview of systematic reviews. BMC Health Services Research, 2022, 22, 401.	2.2	4
3	Systematic review and critical methodological appraisal of community-based falls prevention economic models. Cost Effectiveness and Resource Allocation, 2022, 20, .	1.5	3
4	Conceptualising changes to tobacco and alcohol policy as affecting a single interlinked system. BMC Public Health, 2021, 21, 17.	2.9	6
5	The price of precision: trade-offs between usability and validity in the World Health Organization Health Economic Assessment Tool for walking and cycling. Public Health, 2021, 194, 263-269.	2.9	4
6	Qualitative research to inform economic modelling: a case study in older people's views on implementing the NICE falls prevention guideline. BMC Health Services Research, 2021, 21, 1020.	2.2	6
7	Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 1073-1080.	3.3	8
8	Adalimumab for non-infectious uveitis: is it cost-effective?. British Journal of Ophthalmology, 2019, 103, 1633-1638.	3.9	5
9	Dexamethasone implant for non-infectious uveitis: is it cost-effective?. British Journal of Ophthalmology, 2019, 103, 1639-1644.	3.9	4
10	Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 29-38.	3.3	12
11	The impact of Type 2 diabetes prevention programmes based on risk identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis. Diabetic Medicine, 2017, 34, 632-640.	2.3	29
12	Cost-effectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK. Diabetic Medicine, 2017, 34, 1136-1144.	2.3	30
13	Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation. BMJ Open, 2017, 7, e014953.	1.9	25
14	A cost-effectiveness analysis of condom distribution programmes for the prevention of sexually transmitted infections in England. Journal of Epidemiology and Community Health, 2017, 71, 897-904.	3.7	5
15	OP131 Cost-Effectiveness Of Dexamethasone And Adalimumab For Uveitis. International Journal of Technology Assessment in Health Care, 2017, 33, 60-61.	0.5	1
16	A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. Health Technology Assessment, 2017, 21, 1-170.	2.8	26
17	A Framework for Developing the Structure of Public Health Economic Models. Value in Health, 2016, 19, 588-601.	0.3	51
18	A systematic literature review of the key challenges for developing the structure of public health economic models. International Journal of Public Health, 2016, 61, 289-298.	2.3	26

#	ARTICLE	IF	CITATIONS
19	Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2016, 34, 673-680.	3.3	25
20	A statistical model to describe longitudinal and correlated metabolic risk factors: the Whitehall II prospective study. <i>Journal of Public Health</i> , 2016, 38, 679-687.	1.8	16
21	Modelling the Economics of Type 2 Diabetes Mellitus Prevention: A Literature Review of Methods. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 239-253.	2.1	17
22	Cost-Effectiveness of Cilostazol, Naftidrofuryl Oxalate, and Pentoxifylline for the Treatment of Intermittent Claudication in People With Peripheral Arterial Disease. <i>Angiology</i> , 2014, 65, 190-197.	1.8	18
23	Methods for handling uncertainty within pharmaceutical funding decisions. <i>International Journal of Systems Science</i> , 2014, 45, 60-68.	5.5	6
24	Using Whole Disease Modeling to Inform Resource Allocation Decisions: Economic Evaluation of a Clinical Guideline for Colorectal Cancer Using a Single Model. <i>Value in Health</i> , 2013, 16, 542-553.	0.3	20
25	Authors' reply: Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (<i>Br J Surg</i> 2012; 99: 1630-1638). <i>British Journal of Surgery</i> , 2013, 100, 1838-1839.	0.3	2
26	Cost-effectiveness of interventions to return employees to work following long-term sickness absence due to musculoskeletal disorders. <i>Journal of Public Health</i> , 2012, 34, 115-124.	1.8	21
27	Systematic review and narrative synthesis of the effectiveness of contraceptive service interventions for young people, delivered in health care settings. <i>Health Education Research</i> , 2012, 27, 1102-1119.	1.9	19
28	Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. <i>British Journal of Surgery</i> , 2012, 99, 1630-1638.	0.3	94
29	Whole Disease Modeling to Inform Resource Allocation Decisions in Cancer: A Methodological Framework. <i>Value in Health</i> , 2012, 15, 1127-1136.	0.3	43
30	Routine Antenatal Anti-D Prophylaxis in Women Who Are Rh(D) Negative: Meta-Analyses Adjusted for Differences in Study Design and Quality. <i>PLoS ONE</i> , 2012, 7, e30711.	2.5	49
31	Development of a Transparent Interactive Decision Interrogator to Facilitate the Decision-Making Process in Health Care. <i>Value in Health</i> , 2011, 14, 768-776.	0.3	22
32	PCN193 Using Whole Disease Modelling to Inform Economic Recommendations for the Detection, Diagnosis, Treatment and Follow-up of Colorectal Cancer. <i>Value in Health</i> , 2011, 14, A469-A470.	0.3	2
33	Antioxidants in the chemoprevention of colorectal cancer and colorectal adenomas in the general population: a systematic review and meta-analysis. <i>Colorectal Disease</i> , 2011, 13, 1085-1099.	1.4	51
34	Cost-Effectiveness of Aspirin, Celecoxib, and Calcium Chemoprevention for Colorectal Cancer. <i>Clinical Therapeutics</i> , 2011, 33, 1289-1305.	2.5	7
35	Views regarding the use of contraception amongst young people in the UK: A systematic review and thematic synthesis. <i>European Journal of Contraception and Reproductive Health Care</i> , 2011, 16, 149-160.	1.5	21
36	Views of contraceptive service delivery to young people in the UK: a systematic review and thematic synthesis. <i>Journal of Family Planning and Reproductive Health Care</i> , 2011, 37, 71-84.	0.8	24

#	ARTICLE	IF	CITATIONS
37	A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.. Health Technology Assessment, 2011, 15, 1-210.	2.8	48
38	Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technology Assessment, 2010, 14, 1-206.	2.8	171
39	A comparison of the World Health Organisation's HEAT model results using a non-linear physical activity dose response function with results from the existing tool. Wellcome Open Research, 0, 7, 7.	1.8	0
40	A comparison of the World Health Organisation's HEAT model results using a non-linear physical activity dose response function with results from the existing tool. Wellcome Open Research, 0, 7, 7.	1.8	0